

MANAGEMENT TEAM

Lewis (Rusty) Williams, MD, PhD
Executive Chairman and Founder

Julia P. Gregory
President and CEO

W. Michael Kavanaugh, MD
Sr. VP Research and Development

Kevin Baker, PhD
VP Pre-Clinical Development

Marc Belsky
VP Finance

Lauretta Cesario
VP Human Resources

Amy Collins, PhD, JD
VP Legal Affairs

Jeff Finer, MD, PhD
VP Discovery

Harold Keer, MD, PhD
VP Clinical Development

Aron Knickerbocker
VP Business Development

Bart Wise, PhD, JD
VP Intellectual Property

Brian Wong, MD, PhD
VP Immunology and Discovery

BOARD OF DIRECTORS

Brian Atwood
Versant Ventures

Jim Blair, PhD
Domain Associates

Brook Byers
Kleiner Perkins Caufield Byers

Fred Cohen, MD, D. Phil
TPG Ventures

Lee Douglas
Co-founder, Cor Therapeutics

Julia P. Gregory
President and CEO

Mark McDade
COO and EVP Global Oprns, UCB SA

Gail Maderis
Former President and CEO, FivePrime

Lewis Williams, MD, PhD
Executive Chairman

SCIENTIFIC ADVISORY BOARD

Stanley Cohen, MD
Stanford University Medical Center

Joseph Goldstein, MD
UT Southwestern Medical School

C. Ronald Kahn, MD
Joslin Diabetes Center
Harvard Medical School

Robert Lefkowitz, MD
Duke University Medical Center

Ronald Levy, MD
Stanford University Medical Center

Daniel Von Hoff, MD
Translational Genomics Research Inst

Arthur Weiss, MD, PhD
UC San Francisco



Employees: 115

PROTEIN MEDICINES FOR LIFE

Five Prime Therapeutics, Inc. is a clinical-stage biotech company discovering innovative protein and antibody therapeutics using its world-class discovery engine. We are building a strong pipeline of first-in-class biologics that currently includes an oncology product in a phase 1 trial and multiple preclinical and research programs in oncology, metabolic disease and immunology. We use our unique discovery platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems. FivePrime is in a strong financial position, having raised \$190M to date from equity investments and through partnerships with major pharmaceutical companies.

PRODUCTS

FP-1039 is a first-in-class and potentially best-in-class biologic targeting the FGF/FGFR pathway in cancer. FP-1039 is a soluble fusion protein designed to neutralize the activity of multiple FGFs and FGF receptors. Tumors of the breast, prostate, lung, ovary, colon and pancreas have been reported to have a strong dependence upon the FGF/FGFR pathway for survival and growth. Clinically, activation of this pathway has been correlated with both decreased survival and time to metastasis in several major cancers and escape from anti-VEGF therapy in patients. A Phase 1 study in advanced solid tumor cancers is underway to test safety and tolerability. Preliminary clinical data from this study were presented at the AACR-NCI-EORTC Molecular Targets and Novel Therapeutics Conference in November 2009.



PIPELINE & THERAPEUTIC PROGRAMS

		Product modality	Discovery	Lead Optimization/ Candidate Selection	Preclinical Development	Clinical Phase I
Oncology	<i>FP-1039</i>	ECD-Fc				
	<i>FPT091</i>	ECD-Fc				
	<i>Partner</i>	Undiscl.				
Immunology	<i>FPT069</i>	ECD-Fc				
	<i>FPA008</i>	MAb				
	<i>IL-34</i>	Protein				
Diabetes	<i>FPT038 series</i>	Protein				
	<i>Partner</i>	Undiscl.				
Others	<i>Partner</i>	Undiscl.				

UNIQUE DISCOVERY ENGINE

FivePrime's proven biologics discovery engine is the industry's most comprehensive platform for interrogating the extracellular proteome. FivePrime's proprietary, comprehensive, high-quality and validated library of all human secreted proteins, extracellular domains of receptors and peptides is the foundation of this engine and currently includes 4,045 proteins and peptides. This unprecedented library is queried using three powerful platforms to identify novel biologic product candidates and antibody targets rapidly:

1. High-content cell-based screening assays designed to model disease states, using primary cells and employing upwards of 30 readouts in a single well.
2. Proprietary RIPPSSSM (Rapid In Vivo Protein Production System) for interrogation of complex biological and medically important systems in animals.
3. Proprietary Ligand/Receptor matching platform to rapidly de-orphanize therapeutically important proteins.

PARTNERING

FivePrime has collaborations with Centocor Research and Development Inc. in osteoarthritis and pulmonary fibrosis and with Pfizer, Inc. in specific areas of oncology and diabetes. FivePrime is seeking a development and commercialization partner for FP-1039. In addition, we welcome interest for additional discovery and development collaborations to fully leverage our robust biologics discovery platform.

For inquiries please contact us at: business.development@fiveprime.com